Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ Mice: Comparison to dopamine receptor agonists

Neuropsychopharmacology

Volumn 37, Issue 2, 2012, Pages 378-389

  Ces, Aurelia ^a   Reiss, David ^b   Walter, Ondine ^b,c   Wichmann, Jürgen ^d   Prinssen, Eric P ^d   Kieffer, Brigitte L ^b,e   Ouagazzal, Abdel Mouttalib ^b,f  

^a INSTITUT CLINIQUE DE LA SOURIS   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e INSERM   (France)

^f CNRS   (France)

Author keywords

dopamine; mice; NOP receptor; prepulse inhibition; startle reflex

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; APOMORPHINE; BANORL 24; HALOPERIDOL; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST; QUINELORANE; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EFFECT; HEARING; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PHARMACOLOGICAL STIMULATION; PREPULSE INHIBITION; PRIORITY JOURNAL; SENSORY GATING; STARTLE REFLEX; TIME; VISION;

ACOUSTIC STIMULATION; ANIMALS; BENZIMIDAZOLES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALOPERIDOL; IMIDAZOLES; LYSINE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHOTIC STIMULATION; PIPERIDINES; RECEPTORS, DOPAMINE; RECEPTORS, OPIOID; SENSORY GATING; SPIRO COMPOUNDS; STARTLE REACTION;

EID: 84856066151     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.175     Document Type: Article

References (77)

1. Aubert L, Reiss D, Ouagazzal AM (2006). Auditory and visual prepulse inhibition in mice: parametric analysis and strain comparisons. Genes Brain Behav 5: 423-431. (Pubitemid 44000927)
2. Baldessarini RJ, Tarazi FI (1996). Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry 3: 301-325. (Pubitemid 26141569)
3. Bongsebandhu-phubhakdi S, Manabe T (2007). The neuropeptide nociceptin is a synaptically released endogenous inhibitor of hippocampal long-term potentiation. J Neurosci 27: 4850-4858. (Pubitemid 46699051)
4. Bora E, Yücel M, Pantelis C (2009). Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophr Bull 36: 36-42.
5. Braff DL (2010). Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci 4: 349-371.
6. Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156: 194-215.
7. Brandies R, Yehuda S (2008). The possible role of retinal dopaminergic system in visual performance. Neurosci Biobehav Rev 32: 611-656. (Pubitemid 351329405)
8. Calo' G, Guerrini R, Rizzi A, Salvadori S, Regoli D (2000). Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129: 1261-1283. (Pubitemid 30175697)
9. Campeau S, Davis M (1995). Prepulse inhibition of the acoustic startle reflex using visual and auditory prepulse: disruption by apomorphine. Psychopharmacology 117: 267-274.
10. Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J et al (2008). Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry 64: 4-10.
11. Cavallini S, Marino S, Beani L, Bianchi C, Siniscalchi A (2003). Nociceptin inhibition of acetylcholine efflux from different brain areas. NeuroReport 14: 2167-2170.
12. Chang WL, Geyer MA, Buell MR, Weber M, Swerdlow NR (2010). The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice. Behav Pharmacol 21: 135-143.
13. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C et al (2007). Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr Drug Targets 8: 117-135. (Pubitemid 46043903)
14. Darland T, Grandy DK (1998). The orphanin FQ system: an emerging target for the management of pain? Br J Anaesth 81: 29-37. (Pubitemid 28359263)
15. DiLoreto Jr D, Ison JR, Bowen GP, Cox C, del Cerro M (1995). A functional analysis of the age-related degeneration in the Fischer 344 rat. Curr Eye Res 14: 303-310.
16. Fénelon G (2008). Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13(Suppl 4): 18-25. (Pubitemid 351532445)
17. Florin S, Suaudeau C, Meunier JC, Costentin J (1996). Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur J Pharmacol 317: 9-13. (Pubitemid 26427007)
18. Gavioli EC, Calo' G (2006). Antidepressant-and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch Pharmacol 372: 319-330.
19. Geyer MA (2006). The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps? Neurotox Res 10: 211-220.
20. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156: 117-154. (Pubitemid 32702206)
21. Goeldner C, Reiss D, Kieffer BL, Ouagazzal AM (2010). Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior. Hippocampus 20: 911-916.
22. Goeldner C, Reiss D, Wichmann J, Kieffer BL, Ouagazzal AM (2009). Activation of nociceptin opioid peptide (NOP) receptor impairs contextual fear learning in mice through glutamatergic mechanisms. Neurobiol Learn Mem 91: 393-401.
23. Goeldner C, Reiss D, Wichmann J, Meziane H, Kieffer BL, Ouagazzal AM (2008). Nociceptin receptor impairs recognition memory via interaction with NMDA receptor-dependent mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in the hippocampus. J Neurosci 28: 2190-2198. (Pubitemid 351317630)
24. Gold JM (2004). Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 72: 21-28. (Pubitemid 39452902)
25. Goto Y, Arai-Otsuki S, Tachibana Y, Ichikawa D, Ozaki S, Takahashi H et al (2006). Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J Med Chem 49: 847-849. (Pubitemid 43221632)
26. Higgins GA, Kew JN, Richards JG, Takeshima H, Jenck F, Adam G et al (2002). A combined pharmacological and genetic approach to investigate the role of orphanin FQ in learning and memory. Eur J Neurosci 15: 911-922. (Pubitemid 35463655)
27. Ichinose T, Lukasiewicz PD (2007). Ambient light regulates sodium channel activity to dynamically control retinal signaling. J Neurosci 27: 4756-4764. (Pubitemid 46663567)
28. Ison JR (2001). The acoustic startle reflex in the mouse: reflex elicitation and reflect modification by preliminary stimuli. In: Willott JF (ed). Handbook of Mouse Auditory Research: From Behavior to Molecular Biology, Ch. 5, CRC Press: Boca Raton. pp 59-82.
29. Ison JR, Bowen GP, del Cerro M (1992). Impoverished stimulus input does not simulate the slowed visual kinetics of retinal damage. Invest Ophthalmol Vis Sci 33: 3114-3120.
30. Ison JR, Bowen GP, del Cerro M (1998). A behavioral study of temporal processing and visual persistence in young and aged rats. Behav Neurosci 112: 1273-1279. (Pubitemid 28519010)
31. Jenck F, Wichmann J, Dautzenberg FM, Moreau JL, Ouagazzal AM, Martin JR et al (2000). Synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc Natl Acad Sci USA 97: 4938-4943. (Pubitemid 30238661)
32. Kamei J, Matsunawa Y, Miyata S, Tanaka S, Saitoh A (2004). Effects of nociceptin on the exploratory behavior of mice in the holeboard test. Eur J Pharmacol 489: 77-87. (Pubitemid 38520074)
33. Kawahara Y, Hesselink MB, van Scharrenburg G, Westerink BH (2004). Tonic inhibition by orphanin FQ/nociceptin of noradrenaline neurotransmission in the amygdala. Eur J Pharmacol 485: 197-200. (Pubitemid 38134415)
34. Kawai F, Horiguchi M, Miyachi E (2011). Dopamine modulates the voltage response of human rod photoreceptors by inhibiting the h current. Invest Ophthalmol Vis Sci 52: 4112-4117.
35. Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, Prinssen EP (2009). Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 34: 2088-2096.
36. Konya H, Masuda H, Itoh K, Nagai K, Kakishita E, Matsuoka A (1998). Modification of dopamine release by nociceptin in conscious rat striatum. Brain Res 788: 341-344. (Pubitemid 28202183)
37. Kuzmin A, Sandin J, Terenius L, Ogren SO (2004). Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors. Br J Pharmacol 141: 132-140. (Pubitemid 38241171)
38. Lambert DG (2008). The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 7: 694-710.
39. Lutfy K, Do T, Maidment NT (2001). Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats. Psychopharmacology 154: 1-7. (Pubitemid 32186508)
40. Mamiya T, Yamada K, Miyamoto Y, Konig N, Watanabe Y, Noda Y et al (2003). Neuronal mechanism of nociceptin-induced modulation of learning and memory: involvement of N-methyl-D-aspartate receptors. Mol Psychiatry 8: 752-765. (Pubitemid 36976433)
41. Manabe T, Noda Y, Mamiya T, Katagiri H, Houtani T, Nishi M et al (1998). Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature 394: 577-581. (Pubitemid 28366832)
42. Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J et al (2005). Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 25: 9591-9601. (Pubitemid 41510900)
43. Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M et al (2004). Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 24: 6659-6666. (Pubitemid 38993885)
44. Marti M, Sarubbo S, Latini F, Cavallo M, Eleopra R, Biguzzi S et al (2010). Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease. Mov Disord 25: 1723-1732.
45. Marti M, Trapella C, Viaro R, Morari M (2007). The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 27: 1297-1307.
46. Meis S (2003). Nociceptin/orphanin FQ: actions within the brain. Neuroscientist 9: 158-168. (Pubitemid 36378622)
47. Narayanan S, Lam H, Carroll FI, Lutfy K (2004). Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats. J Psychiatry Neurosci 29: 116-123. (Pubitemid 38570216)
48. Nir I, Harrison JM, Haque R, Low MJ, Grandy DK, Rubinstein M et al (2002). Dysfunctional light-evoked regulation of cAMP in photoreceptors and abnormal retinal adaptation in mice lacking dopamine D4 receptors. J Neurosci 22: 2063-2073. (Pubitemid 35386507)
49. Ouagazzal A-M, Grottick AJ, Moreau J-L, Higgins GA (2001a). Effect of LSD on prepulse inhibition and spontaneous behaviour in the rat: a pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 25: 565-575. (Pubitemid 32830961)
50. Ouagazzal A-M, Jenck F, Moreau J-L (2001b). Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology 156: 273-283. (Pubitemid 32702218)
51. Ouagazzal A-M, Moreau J-L, Pauly-Evers M, Jenck F (2003). Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene. Behav Brain Res 144: 111-117. (Pubitemid 37011172)
52. Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D et al (2000). In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 402: 45-53. (Pubitemid 30625309)
53. Powell SB, Zhou X, Geyer MA (2009). Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 204: 282-294.
54. Ralph RJ, Caine SB (2005). Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther 312: 733-741. (Pubitemid 40189573)
55. Ralph RJ, Caine SB (2007). Effects of selective dopamine D1-like and D2-like agonists on prepulse inhibition of startle in inbred C3H/HeJ, SPRET/EiJ, and CAST/EiJ mice. Psychopharmacology 191: 731-739. (Pubitemid 46355880)
56. Ralph RJ, Paulus MP, Geyer MA (2001). Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice. J Pharmacol Exp Ther 298: 148-155. (Pubitemid 32574521)
57. Ralph-Williams RJ, Lehmann-Masten V, Geyer MA (2003). Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology 28: 108-118.
58. Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer MA (2002). Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci 22: 9604-9611. (Pubitemid 35356202)
59. Redrobe JP, Calo' G, Guerrini R, Regoli D, Quirion R (2000). [Nphe(1)]-Nociceptin (1-13)-NH(2), a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats. Br J Pharmacol 131: 1379-1384.
60. Richfield EK, Young AB, Penney JB (1989). Comparative distributions of dopamine D-1 and D-2 receptors in the cerebral cortex of rats, cats, and monkeys. J Comp Neurol 286: 409-426. (Pubitemid 19223569)
61. Roozendaal B, Lengvilas R, McGaugh JL, Civelli O, Reinscheid RK (2007). Orphanin FQ/nociceptin interacts with the basolateral amygdala noradrenergic system in memory consolidation. Learn Mem 14: 29-35. (Pubitemid 46203564)
62. Schlicker E, Morari M (2000). Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system. Peptides 21: 1023-1029.
63. Seeman P (2010). Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4: 56-73.
64. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51: 139-154. (Pubitemid 24985903)
65. Swerdlow NR, Geyer MA (1998). Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24: 285-301. (Pubitemid 28404986)
66. Swerdlow NR, Geyer MA, Braff DL (2001). Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156: 194-215. (Pubitemid 32702213)
67. Taylor MK, Ison IR, Schwarzkopf SB (1995). Effects of single and repeated exposure to apomorphine on the acoustic startle reflex and its inhibition by visual prepulse. Psychopharmacology 120: 117-127.
68. Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M (2008). Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis 30: 430-438.
69. Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH (2008). The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 23: 1922-1925.
70. Volta M, Mabrouk OS, Bido S, Marti M, Morari M (2010). Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice. J Neurochem 115: 1543-1555.
71. Volta M, Viaro R, Trapella C, Marti M, Morari M (2011). Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity. Exp Neurol 228: 126-137.
72. Weber M, Swerdlow NR (2008). Rat strain differences in startle gating-disruptive effects of apomorphine occur with both acoustic and visual prepulses. Pharmacol Biochem Behav 88: 306-311. (Pubitemid 350116257)
73. Wecker JR, Ison JR (1986). Visual function measured by reflex modification in rats with inherited retinal dystrophy. Behav Neurosci 100: 679-684. (Pubitemid 17208204)
74. Wei WZ, Xie CW (1999). Orphanin FQ suppresses NMDA receptor-dependent long-term depression and depotentiation in hippocampal dentate gyrus. Learn Mem 6: 467-477.
75. Weintraub D, Hurtig HI (2007). Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry 164: 1491-1498. (Pubitemid 350069725)
76. Witkovsky P (2004). Dopamine and retinal function. Doc Ophthalmol 108: 17-40. (Pubitemid 38461014)
77. Zahodne LB, Fernandez HH (2008). Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 25: 665-682.